Patient description: The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is 165 cm tall and her weight is 113 kg. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She doesn't smoke or use any drugs. She likes to try diets and exercise to lose weight. She completed the four square step test in 14 seconds. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her labs: FBS: 98 mg/dl TG: 150 mg/dl Cholesterol: 180 mg/dl LDL: 90 mg/dl HDL: 35 mg/dl Her cardiac assessment is normal. Her joints and ROM are within normal.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Healthy Healthy male volunteers aged ≥20 to ≤45 years 2. Body mass Index (BMI) of 19 to 28kg/m2 ; and a total body weight ≥ 50kg 3. Medically healthy without clinically significant vital signs (blood pressure in sitting position, heart rate) mmHg ≤ Systolic blood pressure (SBP) ≤ 140 mmHg mmHg ≤ Diastolic blood pressure (DBP) ≤ 95 mmHg (beats/min) ≤ Heart rate ≤ 95 (beats/min) 4. Understand restriction during the study and voluntarily consent to participate in the study 5. Consent to use the effective contraceptive methods (using abstinence, spermicide, and condom) and not to donate sperm during the study and until 30 days after completion of study 6. Non-smoker or ex-smoker who stopped smoking for at least one year 7. Negative H. pylori result in urea breath test (UBT)  History of clinically significant diseases in the digestive, kidney, liver, nervous, hemato-oncologic, endocrine, respiratory, immune, psychiatric, musculoskeletal, or cardiovascular system and other diseases that may harm safety of the subject or may affect the validity of study results, in the judgment of investigator 2. History of allergy or hypersensitivity to any drugs including serious adverse events from treatments such as PPI (omeprazole, rabeprazole, lansoprazole) or P-CAB 3. History surgery that may affect absorption, distribution, metabolism, and elimination of the study drug or in such a medical condition, at the discretion of the principal investigator or sub-investigator 4. History of use of another investigational product within 90 days prior to screening visit 5. Donation of a unit of whole blood within 60 days or blood components or transfusion within 30 days prior to screening visit 6. Having special diet or changes in dietary habits within 30 days prior to screening visit 7. Use of prescription drug within 14 days or over-the-count (OTC) drug including herbal medicine within 7 days prior to screening visit 8. Alcohol > 21 units/week 9. Caffeinated drink intake > 5units/day 10. Positive on urinary drug screening test or urine nicotine test 11. Positive human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or syphilis test 12. Clinically significant abnormal result of liver function (serum ALT, AST or total bilirubin levels ≥ 1.5 times the upper limit of normal (ULN)) 13. Inability to tolerate pH catheter insertion 14. History of symptomatic GERD, erosive esophagitis (EE), duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison Syndrome 15. Any other conditions which would have made the subject unsuitable for the study in the opinion of the investigator